Statin use in aortic aneurismal disease to prevent progression and cardiovascular events: Review of experimental and clinical data

Current Vascular Pharmacology

Volumn 11, Issue 3, 2013, Pages 299-304

  de Céniga, Melina Vega ^a   Blanco Colio, Luis M ^b   Tuñón, Jose ^b   Egido, Jesus ^b   Martín Ventura, José L ^b  

^a HOSPITAL DE GALDAKAO   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Abdominal aortic aneurysm; Aneurysmal growth; Cardiovascular events; Immune inflammatory responses; Oxidative stress; Pathophysiology; Proteolysis; Statins; Thrombus

Indexed keywords

ATORVASTATIN; CELECOXIB; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIMVASTATIN; THROMBOPLASTIN;

ABDOMINAL AORTA ANEURYSM; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DEATH; DISEASE COURSE; DRUG MEGADOSE; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; LEUKOCYTE AGGREGATION; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS;

AGED; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84878646130     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311030004     Document Type: Review

References (100)

1. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet 2005; 365: 1577-1589.
2. Powell JT, Brown LC, Forbes JF, et al. Final 12-year follow-up of surgery vs. surveillance in the UK Small Aneurysm Trial. Br J Surg 2007; 94: 702-708.
3. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation 2008; 117: 1883-1889.
4. Michel JB, Martin-Ventura JL, Egido J, et al.; For the FAD EU consortium. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res 2011; 90: 18-27.
5. Parr A, McCann M, Bradshaw B, Shahzad A, Buttner P, Golledge J. Thrombus volume is associated with cardiovascular events and aneurysm growth in patients who have abdominal aortic aneu-rysms. J Vasc Surg 2011; 53: 28-35.
6. THE 4S INVESTIGATORS: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
7. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis 2004; 15: 251-8.
8. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33: 1294-1304.
9. Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003; 63: 12-23.
10. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coen-zyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96: 24F-33F.
11. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from patho- physiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
12. Lindholt JS, Shi GP. Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31: 453-463.
13. Henkel T, Machleidt T, Alkalay I, Krönke M, Ben-Neriah Y, Baeuerle PA. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature 1993; 365: 182-185.
14. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
15. Nakashima H, Aoki M, Miyake T, et al. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligode-oxynucleotides suppressing activity of nuclear factor kappaB and ets transcription factors. Circulation 2004; 109: 132-138.
16. Kalyanasundaram A, Elmore JR, Manazer JR, et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 2006; 43: 117-124.
17. Middleton RK, Bown MJ, Lloyd GM, Jones JL, London NJ, Sayers RD. Characterisation of Interleukin-8 and monocyte chemoattrac-tant protein-1 expression within the abdominal aortic aneurysm and their association with mural inflammation. Eur J Vasc Endovasc Surg 2009; 37: 46-55.
18. Shiraya S, Miyake T, Aoki M, et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvas-tatin through inhibition of macrophage migration. Atherosclerosis 2009; 202: 34-40.
19. Houard X, Touat Z, Ollivier V, et al. Mediators of neutrophil recruitment in human abdominal aortic aneurysms. Cardiovasc Res 2009; 82: 532-541.
20. Tilson MD. The polymorphonuclear leukocyte and the abdominal aortic aneurysm: a neglected cell type and a neglected disease. Circulation 2005; 112: 154-156.
21. Baetta R, Corsini A. Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis 2010; 210: 1-13.
22. Hannawa KK, Eliason JL, Woodrum DT, et al. L-selectin-mediated neutrophil recruitment in experimental rodent aneurysm formation. Circulation 2005; 112: 241-7.
23. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010; 122: 1837-45.
24. Fontaine V, Touat Z, Mtairag el M, et al. Role of leukocyte elastase in preventing cellular re-colonization of the mural thrombus. Am J Pathol 2004; 164: 2077-87.
25. Leclercq A, Houard X, Philippe M, et al. Involvement of intra-plaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol 2007; 82: 1420-9.
26. Zhang S, Rahman M, Zhang S, Qi Z, Herwald H, Thorlacius H. Simvastatin regulates CXC chemokine formation in streptococcal M1 protein-induced neutrophil infiltration in the lung. Am J Physiol Lung Cell Mol Physiol 2011; 300: L930-9.
27. Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med 1999; 106: 37S-42S.
28. Schönbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-91.
29. Gitlin JM, Trivedi DB, Langenbach R, Loftin CD. Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res 2007; 73: 227-36
30. King VL, Trivedi DB, Gitlin JM, Loftin CD. Selective cyclooxy-genase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006; 26: 1137-43.
31. Hernández-Presa MA, Martín-Ventura JL, Ortego M, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002; 160: 49-58.
32. Walton LJ, Franklin IJ, Bayston T, et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999; 100: 48-54.
33. Bayston T, Ramessur S, Reise J, Jones KG, Powell JT. Prostaglan-din E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J Vasc Surg 2003; 38: 354-9.
34. Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005; 36: 1796-800.
35. Gómez-Hernández A, Sánchez-Galán E, Martín-Ventura JL, et al. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. J Cardiovasc Pharmacol 2006; 47: 60-9.
36. Gómez-Hernández A, Sánchez-Galán E, Ortego M, et al. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metal-loproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. Am J Cardiol 2008; 102: 12-8.
37. Muñoz-García B, Moreno JA, López-Franco O, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2009; 29: 2061-8.
38. Martín-Ventura JL, Lindholt JS, Moreno JA, et al. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis 2011; 214: 486-9.
39. Muñoz-García B, Martín-Ventura JL, Martínez E, et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 2006; 37: 2044-53.
40. Touat Z, Ollivier V, Dai J, et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneu-rysm evolution. Am J Pathol 2006; 168: 1022-30.
41. Mitsios JV, Papathanasiou AI, Goudevenos JA, Tselepis AD. The antiplatelet and antithrombotic actions of statins. Curr Pharm Des 2010; 16: 3808-14.
42. Zawadzki C, Susen S, Richard F, et al. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins. Atherosclerosis 2007; 195: e117-25.
43. Camino-López S, Llorente-Cortés V, Sendra J, Badimon L. Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells. Cardiovasc Res 2007; 73: 208-16.
44. Zhang S, Rahman M, Zhang S, Qi Z, Thorlacius H. Simvastatin antagonizes CD40L secretion, CXC chemokine formation, and pulmonary infiltration of neutrophils in abdominal sepsis. J Leukoc Biol 2011; 89: 735-42.
45. Houard X, Touat Z, Ollivier V, et al. Mediators of neutrophil recruitment in human abdominal aortic aneurysms. Cardiovasc Res 2009; 82: 532-41.
46. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler Thromb Vasc Biol 2002; 22: 1029-35.
47. Miller FJ Jr, Sharp WJ, Fang X, Oberley LW, Oberley TD, Wein-traub NL. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodeling. Arterioscler Thromb Vasc Biol 2002; 22: 560-5.
48. McCormick ML, Gavrila D, Weintraub NL. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterio-scler Thromb Vasc Biol 2007; 27: 461-9.
49. Pignatelli P, Carnevale R, Cangemi R, et al. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2010; 30: 360-7.
50. Kumar AP, Reynolds WF. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 2005; 331: 442-51.
51. Dubick MA, Keen CL, DiSilvestro RA, Eskelson CD, Ireton J, Hunter GC. Antioxidant enzyme activity in human abdominal aortic aneurysmal and occlusive disease. Proc Soc Exp Biol Med 1999; 220: 39-45.
52. Martinez-Pinna R, Lindholt JS, Blanco-Colio LM, et al. Increased levels of thioredoxin in patients with abdominal aortic aneurysms (AAA). A potential link of oxidative stress with AAA evolution. Atherosclerosis 2010; 212: 333-8.
53. Martinez-Pinna R, Ramos-Mozo P, Madrigal-Matute J, et al. Identification of peroxiredoxin-1 as a novel biomarker of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 2011; 31: 935-43.
54. Ota H, Eto M, Kano MR, et al. Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol 2010; 30: 2205-11.
55. Fontaine V, Jacob MP, Houard X, et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002; 161: 1701-10.
56. Fontaine V, Touat Z, Mtairag el M, et al. Role of leukocyte elastase in preventing cellular re-colonization of the mural thrombus. Am J Pathol 2004; 164: 2077-87.
57. Steinmetz EF, Buckley C, Shames ML, et al. Treatment with sim-vastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005; 241: 92-101.
58. Kajimoto K, Miyauchi K, Kasai T, et al. Short-term 20-mg atorvas-tatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis 2009; 206: 505-11.
59. Arikan MC, Shapiro SD, Mariani TJ. Induction of macrophage elastase (MMP-12) gene expression by statins. J Cell Physiol 2005; 204: 139-45.
60. Powell JT, Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM. Are we ignoring the importance of ankle pressures in patients with abdominal aortic aneurysm? Eur J Vasc Endovasc Surg 2001; 21: 65-9.
61. Golledge J, Powell JT. Medical management of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2007; 34: 267-73.
62. Shaper AG, Wannamethee SG, Walker M. Pipe and cigar smoking and major cardiovascular events, cancer incidence and all-cause mortality in middle-aged British men. Int J Epidemiol 2003; 32: 802-8.
63. Saratzis A, Saratzis N, Melas N, Kiskinis D. Pharmacotherapy before and after endovascular repair of abdominal aortic aneu-rysms. Curr Vasc Pharmacol 2008; 6: 240-9.
64. The United Kingdom Small Aneurysm Trial Participants. Long term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346: 1445-52.
65. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Are statins an option in the management of abdominal aortic aneurysms? Vasc Endovasc Surg 2008; 42: 128-34.
66. Svensjö S, Björck M, Gürtelschmid M, Djavani Gidlund K, Hell-berg A, Wanhainen A. Low prevalence of abdominal aortic aneu-rysm among 65-year-old swedish men indicates a change in the epidemiology of the disease. Circulation 2011; 124: 1118-23.
67. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006; 97: 279-80.
68. Powell JT. Non-operative or medical management of abdominal aortic aneurysm. Scand J Surg 2008; 97: 121-4.
69. Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004; 116: 96-103.
70. Durazzo AE, Machado FS, Ikeoka DT, et al. Effect of atorvastatin on cardiovascular events after vascular surgery. J Vasc Surg 2004; 39: 967-75.
71. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major non-cardiac vascular surgery. Circulation 2003; 107: 1848-51.
72. McNally MM, Agle SC, Parker FM, et al. Preoperative statin therapy is associated with improved outcomes and resource utilization in patients undergoing aortic aneurysm repair. J Vasc Surg 2010; 51: 1390-6.
73. Moulakakis KG, Matoussevitch V, Borgonio A, Gawenda M, Brunkwall J. Evidence that statins protect renal function during en-dovascular repair of AAAs. Eur J Vasc Endovasc Surg 2010; 40: 608-15.
74. Liapis CD, Kakisis JD, Dimitroulis DA, Daskalopoulos M, Niko-laou A, Kostakis AG. Carotid ultrasound findings as a predictor of long-term survival after abdominal aortic aneurysm repair: A 14-year prospective study. J Vasc Surg 2003; 38: 1220-5.
75. Vega de Céniga M, Estallo L, Barba A, de la Fuente N, Viviens B, Gómez R. Long-term cardiovascular outcome after elective abdominal aortic aneurysm open repair. Ann Vasc Surg 2010; 24: 655-62.
76. Welten GM, Schouten O, Hoeks SE, et al. Long-term prognosis of patients with peripheral arterial disease. A comparison in patients with coronary artery disease. J Am Coll Cardiol 2008; 51: 1588-96.
77. Biancari F, Ylönen K, Anttila V, et al. Durability of open repair of infrarenal abdominal aortic aneurysm: A 15-year follow-up study. J Vasc Surg 2002; 35: 87-93.
78. Koskas F, Kieffer E, for the AURC: Long-term survival after elective repair of infrarenal abdominal aortic aneurysm: results of a prospective multicentric study. Ann Vasc Surg 1997; 11: 473-81.
79. Cappeller WA, Hölzel D, Hinz MH, Lauterjung L. Ten-year results following elective surgery for abdominal aortic aneurysm. Int An-giol 1998; 17: 234-40.
80. Batt M, Staccini P, Pittaluga P, Ferrari E, Hassen-Khodja R, De-clemy S. Late survival after abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 1999; 17: 338-42.
81. Norman PE, Semmens JB, Lawrence-Brown MMD. Long-term relative survival following surgery for abdominal aortic aneurysm: a review. Cardiovasc Surg 2001; 9: 219-24.
82. Mani K, Björck M, Lundkvist J, Wanhainen A. Improved long-term survival after abdominal aortic aneurysm repair. Circulation 2009; 120: 201-11.
83. Leurs LJ, Visser P, Laheij RJ, Buth J, Harris PL, Blankensteijn JD. Statin use is associated with reduced all-cause mortality after endo-vascular abdominal aortic aneurysm repair. Vascular 2006; 14: 1-8.
84. Kapoor AS, Kanji H, Buckingham J, Devereaux PJ, McAlister FA. Strength of evidence for perioperative use of statins to reduce cardiovascular risk: systematic review of controlled studies. Br Med J 2006; 333: 1149-52.
85. Schouten O, Lever TM, Welten GM, et al. Long-term cardiac outcome in high-risk patients undergoing elective endovascular or open infrarenal abdominal aortic aneurysm repair. Eur J Vasc En-dovasc Surg 2008; 36: 646-52.
86. Stalenhoef AFH. The benefit of statins in non-cardiac vascular surgey patients. J Vasc Surg 2009; 49: 260-5
87. Mosorin M, Niemelä E, Heikkinen J, et al. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Tho-rac Surg 2008; 7: 578-81.
88. Twine CP, Williams IM. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg 2011; 98: 346-53
89. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm. Pathogenesis and implications for management. Arterio-scler Thromb Vasc Biol 2006; 26: 2605-13.
90. Ferguson CD, Clancy P, Bourke B, et al. Association of statin prescription with abdominal aortic aneurysm progression. Am Heart J 2010; 159: 307-13.
91. Van Kuijk JP, Flu WJ, Witteveen OP, Voute M, Bax JJ, Polder-mans D. The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms. J Cardiovasc Surg (Torino) 2009; 50: 599-609.
92. Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006; 32: 21-6.
93. Karlsson L, Gnarpe J, Bergqvist D, Lindbäck J, Pärsson H. The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms - a prospective randomized double-blind trial. J Vasc Surg 2009; 50: 23-9.
94. Schlösser FJ, Tangelder MJ, Verhagen HJ, et al.; SMART study group. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg 2008; 47: 1127-33.
95. Golledge J, van Bockxmeer F, Jamrozik K, McCann M, Norman PE. Association between serum lipoproteins and abdominal aortic aneurysm. Am J Cardiol 2010; 105: 1480-4.
96. Hurks R, Hoefer IE, Vink A, et al. Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology. Eur J Vasc Endovasc Surg 2010; 39: 569-76.
97. Bergqvist D. Pharmacological interventions to attenuate the expansion of abdominal aortic aneurysm (AAA) - a systematic review. Eur J Vasc Endovasc Surg 2011; 41: 663-7.
98. Takagi H, Matsui M, Umemoto T. A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion. J Vasc Surg 2010; 52: 1675-81.
99. Wang JA, Chen WA, Wang Y, et al. Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms. Atherosclerosis 2011; 217: 90-6.
100. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Patho-physiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol 2011; 8: 92-102.